Got a Dense-Breast Notice After Your Mammogram? What a New Study Says About When MRI May Help

If you got a letter after your mammogram saying your breasts are dense, the most important takeaway is this: it is a prompt for a risk discussion, not an automatic order for an MRI.

That question has become more common since a federal FDA rule began being enforced on September 10, 2024, requiring mammography facilities nationwide to tell patients whether their breast tissue is dense. Now a new study, published March 3, 2026 in Annals of Internal Medicine, offers a more specific answer to the question many people ask next: should dense breasts mean extra screening with MRI?

The short answer is no, not for everyone. The study suggests the strongest potential benefit was in women with extremely dense breasts who also had higher-than-average breast cancer risk. Dense tissue by itself did not automatically make MRI the best next step.

Why so many people are asking about MRI now

Under the FDA’s mammography rules, patients must now be told whether their breast tissue is dense or not dense. For many people, that notice can sound alarming, especially because it says other imaging tests may help in some cases.

But the notice is meant to start a conversation, not to tell every patient to get more testing. The FDA language itself says to talk with a healthcare provider about breast density, breast cancer risk, and your individual situation.

That matters because breast density is only one piece of risk. Family history, inherited mutations such as BRCA-related risk, prior high-risk biopsy findings, prior chest radiation at a young age, and personal breast cancer history can all change what screening plan makes sense.

What “dense breasts” means in plain language

Breast density describes how much fibrous and glandular tissue shows up on a mammogram compared with fatty tissue. It is not something you can feel by touch, and it does not mean your breasts are abnormal.

Radiologists sort breast density into four categories:

almost entirely fatty
scattered areas of fibroglandular density
heterogeneously dense
extremely dense

The last two categories are considered “dense.” According to the CDC, about half of women age 40 and older have dense breasts.

Why density matters

Density matters for two reasons.

First, dense breasts are linked to a somewhat higher risk of breast cancer. Second, dense tissue can make mammograms harder to read because both dense tissue and tumors can look white on the image. In other words, dense tissue can partly hide a cancer.

That masking effect is one reason experts increasingly talk about more precise, risk-based screening instead of a one-size-fits-all approach. But “dense” is not all one group. Someone with heterogeneously dense breasts is not the same as someone with extremely dense breasts, and overall cancer risk still matters.

What the new March 2026 study actually looked at

The new Annals of Internal Medicine paper was not a randomized clinical trial. It was a simulation or modeling study. That means researchers used data from the Breast Cancer Surveillance Consortium and other published evidence to estimate what might happen over a lifetime under different screening strategies.

The model focused on women age 40 and older in the United States. It compared digital breast tomosynthesis, also called 3D mammography, with or without supplemental MRI. It also looked at different starting ages, screening intervals, breast density levels, and cancer risk levels ranging from average risk to four times average risk.

Researchers estimated outcomes such as breast cancer deaths averted, false-positive biopsy recommendations, and cost-effectiveness.

That makes the study useful, but it also puts limits on how far we should take it. Models depend on assumptions. They estimate outcomes rather than directly measuring what happened to real patients in a trial. The authors also noted that the subgroups in the model considered breast density and overall risk, but not every factor that can shape screening decisions in real life.

What the study found

The headline finding was not that all women with dense breasts should get MRI. Instead, the most favorable balance in the model appeared in women with extremely dense breasts and at least roughly double average breast cancer risk.

In the study’s conclusion, supplemental MRI for women with extremely dense breasts and higher-than-average risk had harm-benefit ratios similar to biennial 3D mammography alone and could be cost-effective if MRI costs and false-positive biopsy rates were lower.

That is a narrower message than many readers may expect. It does not mean every person with a dense-breast notice should add MRI. It also does not mean the study proved MRI saves lives for all women with dense breasts.

The model also showed tradeoffs. Across different ages and screening intervals, adding MRI for women with extremely dense breasts prevented a small additional number of breast cancer deaths but also led to many more false-positive biopsy recommendations.

Why more screening is not automatically better

MRI is a very sensitive test. That can be helpful, especially for people at higher risk. But higher sensitivity also means more findings that turn out not to be cancer.

For patients, that can mean:

more call-backs after screening
more follow-up imaging
more biopsy recommendations
more anxiety while waiting for answers
more cost

The CDC notes that extra tests after a mammogram are more likely to produce false-positive results, which can lead to unnecessary testing and biopsies. The new study reached a similar conclusion from a modeling perspective: whether MRI looked cost-effective depended heavily on MRI price and on how often it triggered false-positive biopsy recommendations.

That is why “more screening” is not always the same as “better screening.” The goal is to find the people most likely to benefit without causing a large amount of extra harm, cost, and stress for everyone else.

What current U.S. guidance says

Current U.S. guidance does not treat dense breasts alone as an automatic reason for extra screening.

ACOG says it does not recommend routine extra screening for people who have dense breasts but no other risk factors and no symptoms. That is because evidence has not clearly shown that adding other tests for dense breasts alone reduces deaths from breast cancer.

So if your report says your breasts are dense, the next question is not simply, “Should I get an MRI?” The better question is, “What is my overall breast cancer risk, and how should that change my screening plan?”

Questions to ask after a dense-breast notice

If you get a dense-breast notice, it may help to ask your clinician:

Do I have heterogeneously dense breasts or extremely dense breasts?
How does my family history affect my risk?
Do I have any personal history, biopsy findings, or genetic factors that put me at higher risk?
Would MRI, ultrasound, or no extra test be most appropriate for me?
Will my insurance cover supplemental screening, and what could I owe out of pocket?

Coverage can vary, and extra imaging may still bring out-of-pocket costs depending on the test, the plan, and where you receive care. That is worth checking before scheduling additional screening.

What this means for readers

A dense-breast letter should not be ignored, but it also should not trigger panic.

Dense breasts are common. They can modestly raise breast cancer risk and make mammograms harder to read. But the new March 2026 study does not support automatic MRI for everyone with dense tissue.

Its main message is more targeted: supplemental MRI may make the most sense for people with extremely dense breasts who also have other risk factors that put them above average risk.

For everyone else, the best next step is usually a conversation about overall risk, not a rush into more imaging. And none of this means you should skip mammograms. Mammography remains the starting point for screening, with extra tests considered when the likely benefit is high enough to outweigh the added false alarms, biopsies, and costs.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.